Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-05-08

AUTHORS

Steven R. Feldman, Haijun Tian, Isabelle Gilloteau, Patrick Mollon, Meng Shu

ABSTRACT

BackgroundPsoriasis is a multifactorial, inflammatory, skin disease associated with various comorbidities. The cost of those comorbidities is not well characterized. The present study assesses the incremental burden of comorbidities on healthcare resource utilization, direct costs and indirect costs associated with short-term disabilities among patients with psoriasis in the United States.MethodsA retrospective, U.S. cohort analysis was conducted using a large claims database. Adult psoriasis patients with at least two diagnoses of psoriasis during the years 2010 and 2011 (one psoriasis diagnosis had to happen in the year 2010) and with continuous enrollment of medical and pharmacy benefits in the years 2010 and 2011 were included. Psoriasis patients were categorized and compared according to the presence or absence of pre-selected comorbidities in the year 2010. Adjusted annual direct (costs associated with outpatient, emergency room, and inpatient claims, and outpatient pharmacy claims) and indirect costs (short-term disabilities) was assessed in patients with and without comorbidities using a regression analysis, controlling for age, gender, and psoriasis severity in year 2010.ResultsIn total, 56,406 patients (mean [SD]) age, 51.6 [14.6] years) were included in the analysis. The most prevalent comorbidities were hypertension (34.3%), hyperlipidemia (33.5%), cardiovascular disease (17.7%), diabetes (14.2%), and psoriatic arthritis (9.9%). Psoriasis patients with comorbidities used more healthcare resources than those without comorbidities. The incidence rate ratio (IRR) (95% CI) for patients with cardiovascular disease was 1.5 (1.4 − 1.5) for outpatient visits, 2.6 (2.4 − 2.8) for hospitalizations, and 2.3 (2.2 − 2.5) for ER visits, showing higher IRRs across all three types of resource use. The mean annual adjusted direct cost differences (i.e., incremental adjusted costs) in psoriasis patients with and without comorbidities were $9914.3, $8386.5, and $8275.1 for psoriatic arthritis, peripheral vascular disease, and cardiovascular disease, respectively. The mean annual incremental adjusted indirect costs of short-term disabilities were $1333, $1195, $994.9, and $996.6 for cerebrovascular disease, obesity, peripheral vascular disease, and depression, respectively.ConclusionThe presence of comorbidities was associated with higher healthcare resource utilization and costs among patients with psoriasis. More... »

PAGES

337

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12913-017-2278-0

DOI

http://dx.doi.org/10.1186/s12913-017-2278-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085209002

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28482887


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Databases, Factual", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Care Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperlipidemias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Obesity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psoriasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regression Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, Wake Forest University School of Medicine, 4618 Country Club Road, Winston-Salem, North Carolina, USA", 
          "id": "http://www.grid.ac/institutes/grid.241167.7", 
          "name": [
            "Department of Dermatology, Wake Forest University School of Medicine, 4618 Country Club Road, Winston-Salem, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feldman", 
        "givenName": "Steven R.", 
        "id": "sg:person.01355465361.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355465361.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tian", 
        "givenName": "Haijun", 
        "id": "sg:person.01276713212.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276713212.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilloteau", 
        "givenName": "Isabelle", 
        "id": "sg:person.01121723750.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121723750.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mollon", 
        "givenName": "Patrick", 
        "id": "sg:person.012225427653.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012225427653.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Beijing Novartis Pharma Co. Ltd., Beijing, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Beijing Novartis Pharma Co. Ltd., Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shu", 
        "givenName": "Meng", 
        "id": "sg:person.015574475255.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015574475255.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00128071-200506060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010950854", 
          "https://doi.org/10.2165/00128071-200506060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nutd.2012.26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008240116", 
          "https://doi.org/10.1038/nutd.2012.26"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-05-08", 
    "datePublishedReg": "2017-05-08", 
    "description": "BackgroundPsoriasis is a multifactorial, inflammatory, skin disease associated with various comorbidities. The cost of those comorbidities is not well characterized. The present study assesses the incremental burden of comorbidities on healthcare resource utilization, direct costs and indirect costs associated with short-term disabilities among patients with psoriasis in the United States.MethodsA retrospective, U.S. cohort analysis was conducted using a large claims database. Adult psoriasis patients with at least two diagnoses of psoriasis during the years 2010 and 2011 (one psoriasis diagnosis had to happen in the year 2010) and with continuous enrollment of medical and pharmacy benefits in the years 2010 and 2011 were included. Psoriasis patients were categorized and compared according to the presence or absence of pre-selected comorbidities in the year 2010. Adjusted annual direct (costs associated with outpatient, emergency room, and inpatient claims, and outpatient pharmacy claims) and indirect costs (short-term disabilities) was assessed in patients with and without comorbidities using a regression analysis, controlling for age, gender, and psoriasis severity in year 2010.ResultsIn total, 56,406 patients (mean [SD]) age, 51.6 [14.6] years) were included in the analysis. The most prevalent comorbidities were hypertension (34.3%), hyperlipidemia (33.5%), cardiovascular disease (17.7%), diabetes (14.2%), and psoriatic arthritis (9.9%). Psoriasis patients with comorbidities used more healthcare resources than those without comorbidities. The incidence rate ratio (IRR) (95% CI) for patients with cardiovascular disease was 1.5 (1.4\u2009\u2212\u20091.5) for outpatient visits, 2.6 (2.4\u2009\u2212\u20092.8) for hospitalizations, and 2.3 (2.2\u2009\u2212\u20092.5) for ER visits, showing higher IRRs across all three types of resource use. The mean annual adjusted direct cost differences (i.e., incremental adjusted costs) in psoriasis patients with and without comorbidities were $9914.3, $8386.5, and $8275.1 for psoriatic arthritis, peripheral vascular disease, and cardiovascular disease, respectively. The mean annual incremental adjusted indirect costs of short-term disabilities were $1333, $1195, $994.9, and $996.6 for cerebrovascular disease, obesity, peripheral vascular disease, and depression, respectively.ConclusionThe presence of comorbidities was associated with higher healthcare resource utilization and costs among patients with psoriasis.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12913-017-2278-0", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1327417", 
        "issn": [
          "1472-6963"
        ], 
        "name": "BMC Health Services Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "17"
      }
    ], 
    "keywords": [
      "incidence rate ratios", 
      "healthcare resource utilization", 
      "peripheral vascular disease", 
      "psoriasis patients", 
      "short-term disability", 
      "cardiovascular disease", 
      "psoriatic arthritis", 
      "vascular disease", 
      "indirect costs", 
      "higher healthcare resource utilization", 
      "higher incidence rate ratio", 
      "more healthcare resources", 
      "diagnosis of psoriasis", 
      "large claims database", 
      "adult psoriasis patients", 
      "direct cost differences", 
      "MethodsA retrospective", 
      "patient age", 
      "prevalent comorbidities", 
      "ER visits", 
      "incremental burden", 
      "continuous enrollment", 
      "outpatient visits", 
      "psoriasis severity", 
      "cerebrovascular disease", 
      "claims database", 
      "ConclusionThe presence", 
      "comorbidities", 
      "cohort analysis", 
      "patients", 
      "economic burden", 
      "skin diseases", 
      "healthcare resources", 
      "pharmacy benefits", 
      "disease", 
      "psoriasis", 
      "direct costs", 
      "rate ratio", 
      "U.S. database", 
      "arthritis", 
      "regression analysis", 
      "visits", 
      "year 2010", 
      "present study", 
      "cost differences", 
      "age", 
      "disability", 
      "United States", 
      "burden", 
      "resource utilization", 
      "BackgroundPsoriasis", 
      "hypertension", 
      "hospitalization", 
      "hyperlipidemia", 
      "obesity", 
      "diabetes", 
      "multifactorial", 
      "resource use", 
      "diagnosis", 
      "severity", 
      "depression", 
      "total", 
      "enrollment", 
      "database", 
      "gender", 
      "presence", 
      "years", 
      "retrospective", 
      "absence", 
      "differences", 
      "analysis", 
      "study", 
      "benefits", 
      "utilization", 
      "use", 
      "ratio", 
      "types", 
      "cost", 
      "results", 
      "state", 
      "resources"
    ], 
    "name": "Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database", 
    "pagination": "337", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085209002"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12913-017-2278-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28482887"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12913-017-2278-0", 
      "https://app.dimensions.ai/details/publication/pub.1085209002"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_751.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12913-017-2278-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2278-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2278-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2278-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12913-017-2278-0'


 

This table displays all metadata directly associated to this object as RDF triples.

258 TRIPLES      21 PREDICATES      126 URIs      116 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12913-017-2278-0 schema:about N0232f9903d6b46178dcbbbcd13be56a2
2 N0bb64904810746afb49b1e5a944316e3
3 N2eeccbd6e5a74952b2901eb1ec867ea7
4 N60f5e14b678544b6ba1f17a77e097889
5 N6292d07747e54f2a92f72aaf835a1114
6 N6483abc989604ef4802f4db2ffa5ef0d
7 N9566195263ec43d39765b2bed44f03ef
8 Nae00b28baf8a46569eaf8f7084b86def
9 Nb2dfc596ecaa4117b400132419170d85
10 Nbb8520c1894f4e4f9199dcb0b9991d8f
11 Nc1a946888ebd4822978a9f0207dfe10a
12 Nc45dda0ea3ca40e8bb6d6423976ab19b
13 Nc5825815ff0343f899326fe22cd93cd8
14 Ndc7b7adeb37a46a3a0de4dac3f60cd46
15 Nde292605eb814855b868d617dec288fb
16 Ne0d28c20a6504449bf6176cd92e3b611
17 Ne5d571c925c641a1b5677dd6a4249187
18 Nffbe15b4f3e645e583641b17287bae1f
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author N81e9b8ee2fcb499096934545095989e7
22 schema:citation sg:pub.10.1038/nutd.2012.26
23 sg:pub.10.2165/00128071-200506060-00005
24 schema:datePublished 2017-05-08
25 schema:datePublishedReg 2017-05-08
26 schema:description BackgroundPsoriasis is a multifactorial, inflammatory, skin disease associated with various comorbidities. The cost of those comorbidities is not well characterized. The present study assesses the incremental burden of comorbidities on healthcare resource utilization, direct costs and indirect costs associated with short-term disabilities among patients with psoriasis in the United States.MethodsA retrospective, U.S. cohort analysis was conducted using a large claims database. Adult psoriasis patients with at least two diagnoses of psoriasis during the years 2010 and 2011 (one psoriasis diagnosis had to happen in the year 2010) and with continuous enrollment of medical and pharmacy benefits in the years 2010 and 2011 were included. Psoriasis patients were categorized and compared according to the presence or absence of pre-selected comorbidities in the year 2010. Adjusted annual direct (costs associated with outpatient, emergency room, and inpatient claims, and outpatient pharmacy claims) and indirect costs (short-term disabilities) was assessed in patients with and without comorbidities using a regression analysis, controlling for age, gender, and psoriasis severity in year 2010.ResultsIn total, 56,406 patients (mean [SD]) age, 51.6 [14.6] years) were included in the analysis. The most prevalent comorbidities were hypertension (34.3%), hyperlipidemia (33.5%), cardiovascular disease (17.7%), diabetes (14.2%), and psoriatic arthritis (9.9%). Psoriasis patients with comorbidities used more healthcare resources than those without comorbidities. The incidence rate ratio (IRR) (95% CI) for patients with cardiovascular disease was 1.5 (1.4 − 1.5) for outpatient visits, 2.6 (2.4 − 2.8) for hospitalizations, and 2.3 (2.2 − 2.5) for ER visits, showing higher IRRs across all three types of resource use. The mean annual adjusted direct cost differences (i.e., incremental adjusted costs) in psoriasis patients with and without comorbidities were $9914.3, $8386.5, and $8275.1 for psoriatic arthritis, peripheral vascular disease, and cardiovascular disease, respectively. The mean annual incremental adjusted indirect costs of short-term disabilities were $1333, $1195, $994.9, and $996.6 for cerebrovascular disease, obesity, peripheral vascular disease, and depression, respectively.ConclusionThe presence of comorbidities was associated with higher healthcare resource utilization and costs among patients with psoriasis.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N456ff15d98674aa0ab5468d7a53c17cc
30 N8862323762e6491f91714c36c2c379fe
31 sg:journal.1327417
32 schema:keywords BackgroundPsoriasis
33 ConclusionThe presence
34 ER visits
35 MethodsA retrospective
36 U.S. database
37 United States
38 absence
39 adult psoriasis patients
40 age
41 analysis
42 arthritis
43 benefits
44 burden
45 cardiovascular disease
46 cerebrovascular disease
47 claims database
48 cohort analysis
49 comorbidities
50 continuous enrollment
51 cost
52 cost differences
53 database
54 depression
55 diabetes
56 diagnosis
57 diagnosis of psoriasis
58 differences
59 direct cost differences
60 direct costs
61 disability
62 disease
63 economic burden
64 enrollment
65 gender
66 healthcare resource utilization
67 healthcare resources
68 higher healthcare resource utilization
69 higher incidence rate ratio
70 hospitalization
71 hyperlipidemia
72 hypertension
73 incidence rate ratios
74 incremental burden
75 indirect costs
76 large claims database
77 more healthcare resources
78 multifactorial
79 obesity
80 outpatient visits
81 patient age
82 patients
83 peripheral vascular disease
84 pharmacy benefits
85 presence
86 present study
87 prevalent comorbidities
88 psoriasis
89 psoriasis patients
90 psoriasis severity
91 psoriatic arthritis
92 rate ratio
93 ratio
94 regression analysis
95 resource use
96 resource utilization
97 resources
98 results
99 retrospective
100 severity
101 short-term disability
102 skin diseases
103 state
104 study
105 total
106 types
107 use
108 utilization
109 vascular disease
110 visits
111 year 2010
112 years
113 schema:name Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database
114 schema:pagination 337
115 schema:productId N34143959ec494c17962e320f5c4d61b1
116 N7efd5fe0840e418d9329396fa16a7811
117 Na596fbc5afd44679bed1349abeffc995
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085209002
119 https://doi.org/10.1186/s12913-017-2278-0
120 schema:sdDatePublished 2022-12-01T06:37
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N9b5dd0d135c1478caa16528a9c79ff32
123 schema:url https://doi.org/10.1186/s12913-017-2278-0
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N0232f9903d6b46178dcbbbcd13be56a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Health Services
129 rdf:type schema:DefinedTerm
130 N0bb64904810746afb49b1e5a944316e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Psoriasis
132 rdf:type schema:DefinedTerm
133 N2eeccbd6e5a74952b2901eb1ec867ea7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name United States
135 rdf:type schema:DefinedTerm
136 N34143959ec494c17962e320f5c4d61b1 schema:name pubmed_id
137 schema:value 28482887
138 rdf:type schema:PropertyValue
139 N3b74f133828d4150b3e5884ce05dcbd3 rdf:first sg:person.01121723750.32
140 rdf:rest Na25c0dfb7e1f4dddb78e2288046286b3
141 N409b0014ce514d48bc88784fcba3618c rdf:first sg:person.015574475255.99
142 rdf:rest rdf:nil
143 N456ff15d98674aa0ab5468d7a53c17cc schema:volumeNumber 17
144 rdf:type schema:PublicationVolume
145 N57b9a820102b4f56b4de23617882b4fd rdf:first sg:person.01276713212.90
146 rdf:rest N3b74f133828d4150b3e5884ce05dcbd3
147 N60f5e14b678544b6ba1f17a77e097889 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Databases, Factual
149 rdf:type schema:DefinedTerm
150 N6292d07747e54f2a92f72aaf835a1114 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Prevalence
152 rdf:type schema:DefinedTerm
153 N6483abc989604ef4802f4db2ffa5ef0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Regression Analysis
155 rdf:type schema:DefinedTerm
156 N7efd5fe0840e418d9329396fa16a7811 schema:name dimensions_id
157 schema:value pub.1085209002
158 rdf:type schema:PropertyValue
159 N81e9b8ee2fcb499096934545095989e7 rdf:first sg:person.01355465361.45
160 rdf:rest N57b9a820102b4f56b4de23617882b4fd
161 N8862323762e6491f91714c36c2c379fe schema:issueNumber 1
162 rdf:type schema:PublicationIssue
163 N9566195263ec43d39765b2bed44f03ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Hospitalization
165 rdf:type schema:DefinedTerm
166 N9b5dd0d135c1478caa16528a9c79ff32 schema:name Springer Nature - SN SciGraph project
167 rdf:type schema:Organization
168 Na25c0dfb7e1f4dddb78e2288046286b3 rdf:first sg:person.012225427653.96
169 rdf:rest N409b0014ce514d48bc88784fcba3618c
170 Na596fbc5afd44679bed1349abeffc995 schema:name doi
171 schema:value 10.1186/s12913-017-2278-0
172 rdf:type schema:PropertyValue
173 Nae00b28baf8a46569eaf8f7084b86def schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Cardiovascular Diseases
175 rdf:type schema:DefinedTerm
176 Nb2dfc596ecaa4117b400132419170d85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Female
178 rdf:type schema:DefinedTerm
179 Nbb8520c1894f4e4f9199dcb0b9991d8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Health Care Costs
181 rdf:type schema:DefinedTerm
182 Nc1a946888ebd4822978a9f0207dfe10a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Adult
184 rdf:type schema:DefinedTerm
185 Nc45dda0ea3ca40e8bb6d6423976ab19b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Obesity
187 rdf:type schema:DefinedTerm
188 Nc5825815ff0343f899326fe22cd93cd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Comorbidity
190 rdf:type schema:DefinedTerm
191 Ndc7b7adeb37a46a3a0de4dac3f60cd46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Hyperlipidemias
193 rdf:type schema:DefinedTerm
194 Nde292605eb814855b868d617dec288fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Middle Aged
196 rdf:type schema:DefinedTerm
197 Ne0d28c20a6504449bf6176cd92e3b611 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Retrospective Studies
199 rdf:type schema:DefinedTerm
200 Ne5d571c925c641a1b5677dd6a4249187 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Humans
202 rdf:type schema:DefinedTerm
203 Nffbe15b4f3e645e583641b17287bae1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Male
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1327417 schema:issn 1472-6963
213 schema:name BMC Health Services Research
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01121723750.32 schema:affiliation grid-institutes:grid.419481.1
217 schema:familyName Gilloteau
218 schema:givenName Isabelle
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121723750.32
220 rdf:type schema:Person
221 sg:person.012225427653.96 schema:affiliation grid-institutes:grid.419481.1
222 schema:familyName Mollon
223 schema:givenName Patrick
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012225427653.96
225 rdf:type schema:Person
226 sg:person.01276713212.90 schema:affiliation grid-institutes:grid.418424.f
227 schema:familyName Tian
228 schema:givenName Haijun
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276713212.90
230 rdf:type schema:Person
231 sg:person.01355465361.45 schema:affiliation grid-institutes:grid.241167.7
232 schema:familyName Feldman
233 schema:givenName Steven R.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355465361.45
235 rdf:type schema:Person
236 sg:person.015574475255.99 schema:affiliation grid-institutes:None
237 schema:familyName Shu
238 schema:givenName Meng
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015574475255.99
240 rdf:type schema:Person
241 sg:pub.10.1038/nutd.2012.26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008240116
242 https://doi.org/10.1038/nutd.2012.26
243 rdf:type schema:CreativeWork
244 sg:pub.10.2165/00128071-200506060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010950854
245 https://doi.org/10.2165/00128071-200506060-00005
246 rdf:type schema:CreativeWork
247 grid-institutes:None schema:alternateName Beijing Novartis Pharma Co. Ltd., Beijing, China
248 schema:name Beijing Novartis Pharma Co. Ltd., Beijing, China
249 rdf:type schema:Organization
250 grid-institutes:grid.241167.7 schema:alternateName Department of Dermatology, Wake Forest University School of Medicine, 4618 Country Club Road, Winston-Salem, North Carolina, USA
251 schema:name Department of Dermatology, Wake Forest University School of Medicine, 4618 Country Club Road, Winston-Salem, North Carolina, USA
252 rdf:type schema:Organization
253 grid-institutes:grid.418424.f schema:alternateName Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
254 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
255 rdf:type schema:Organization
256 grid-institutes:grid.419481.1 schema:alternateName Novartis Pharma AG, Basel, Switzerland
257 schema:name Novartis Pharma AG, Basel, Switzerland
258 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...